OneSource secures $95m from leading investors; Strides Pharma shareholders witness surge in embedded value
OneSource Specialty Pharma Limited, previously known as Stelis Biopharma, has received equity commitments amounting to INR 8,010 million (approximately USD 95 million) from prominent institutional investors, thereby positioning the company at a pre-money valuation of USD 1.65 billion. This strategic financial endorsement, led by HBM Healthcare Investments along with substantial contributions from WhiteOak Capital, Param […]
